Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Assembly Biosciences, Inc. ASMB NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$40.00
+35.9%

Assembly Biosciences, Inc. (ASMB) is a Biotechnology company in the Healthcare sector, currently trading at $29.44. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is ASMB = $40 (+35.9% upside).

Valuation: ASMB trades at a trailing Price-to-Earnings (P/E) of -54.6 (S&P 500 average ~25).

Financials: revenue is $72M, +225.8%/yr average growth. Net income is $6M (loss), growing at +50.9%/yr. Net profit margin is -8.5% (negative). Gross margin is 99.8% (+682.5 pp trend).

Balance sheet: total debt is $3M against $207M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.22 (strong liquidity). Debt-to-assets is 1%. Total assets: $258M.

Analyst outlook: 6 / 11 analysts rate ASMB as buy (55%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$40.00
▲ 35.87% Upside
Average Price Target
The 12-month price target for Assembly Biosciences, Inc. is $40.00.

ASMB SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ASMB

✓
VALUE Pass
90/100
ASMB trades at a trailing Price-to-Earnings (P/E) of -54.6 (S&P 500 average ~25). Forward PEG -1.02 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $40, implying +35.9% from the current price $29. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
ASMB: +225.8%/yr revenue is, +50.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ASMB: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 5.22 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
ASMB: Gross margin is 99.8% (+682.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 6 / 11 analysts rate ASMB as buy (55%). Analyst consensus target is $40 (+35.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ASMB: Net profit margin is -8.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range7.75-39.71
Volume80.31K
Avg Volume (30D)96.44K
Market Cap$467M
Beta (1Y)1.16
Share Statistics
EPS (TTM)-0.55
Shares Outstanding$11.21M
IPO Date2010-12-17
Employees73
CEOJason A. Okazaki
Financial Highlights & Ratios
Revenue (TTM)$72.3M
Gross Profit$72.17M
EBITDA$-11.99M
Net Income$-6.12M
Operating Income$-12.12M
Total Cash$248.11M
Total Debt$2.63M
Net Debt$-55.82M
Total Assets$257.59M
Price / Earnings (P/E)-53.5
Price / Sales (P/S)6.46
Analyst Forecast
1Y Price Target$40.00
Target High$40.00
Target Low$40.00
Upside+35.9%
Rating ConsensusBuy
Analysts Covering11
Buy 55% Hold 45% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS0453962070

Price Chart

Track all markets on TradingView
ASMB
Assembly Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
7.75 52WK RANGE 39.71

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message